3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Vascular Diseases
1
Respiratory Tract Diseases
1
Pulmonary Embolism
1
Neoplasms
1
Lung Diseases
1
Embolism and Thrombosis
1
Embolism
1
Disease
1
Cardiovascular Diseases
1
Interventions
entinostat
3
Carboplatin
3
Pemetrexed
2
Bronchoscopy
2
sotorasib
1
pralsetinib
1
pembrolizumab
1
osimertinib
1
lorlatinib
1
ficlatuzumab
1
exemestane
1
demcizumab
1
cobimetinib
1
camrelizumab
1
aflibercept
1
Tyrosine Kinase Inhibitors
1
Thrombin
1
Temozolomide
1
TachoSil
1
Saline Solution
1
Radiomics
1
Paclitaxel
1
One-Lung Ventilation
1
Nutritional Status
1
Microscopy, Confocal
1
Gefitinib
1
Fibrinogen
1
Exercise
1
Erlotinib Hydrochloride
1
Diagnostic Imaging
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Lung Diseases
×
4-((1,4,8,11-tetraazacyclotetradec-1-yl)methyl)benzoic acid
×
Clear all
NCT04657120
2025-12-23
HYDRA
Leiden University Medical Center
Phase NA
Completed
698 enrolled